source
- Gubra aims to expand beyond obesity drugs, targets first portfolio partner this yearCopenhagen‑based biotech Gubra is currently known for its obesity drug candidates, but the company says its long‑term growth will depend on a broader pipeline beyond metabolism. The firm’s existin…
- FDA issues early alert on B. Braun Streamline Bloodline Set recall due to connector leak riskThe FDA's Center for Devices and Radiological Health issued an Early Alert about B. Braun's Streamline Bloodline Set for Dialog+ after discovering a potential high risk issue. The problem is trace…